Peter L Anderson
Overview
Explore the profile of Peter L Anderson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
247
Citations
9157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Horvath K, Helm J, Black A, Chase G, Ma J, Klaphake J, et al.
AIDS Behav
. 2024 May;
28(8):2804-2820.
PMID: 38816592
This randomized controlled study assessed the feasibility, acceptability, and preliminary impact of the PrEP iT! mHealth intervention designed to improve PrEP adherence among young men who have sex with men...
12.
van den Elshout M, Wijstma E, Boyd A, Jongen V, Coyer L, Anderson P, et al.
PLoS Med
. 2024 May;
21(5):e1004328.
PMID: 38718068
Background: An increasing number of countries are currently implementing or scaling-up HIV pre-exposure prophylaxis (PrEP) care. With the introduction of PrEP, there was apprehension that condom use would decline and...
13.
Zhang H, Mock M, Bushman L, Anderson P, Kiser J, Naggie S
Clin Infect Dis
. 2024 May;
79(3):705-708.
PMID: 38703389
This case-control study explored cumulative tenofovir exposure among patients with human immunodeficiency virus/hepatis B virus (HIV/HBV) coinfection with HIV viral suppression. Among patients taking tenofovir disoproxil fumarate, median TFV-DP levels...
14.
Wu L, Kinuthia J, Anderson P, Baeten J, Dettinger J, Gandhi M, et al.
J Infect Dis
. 2024 May;
230(3):689-695.
PMID: 38700101
We evaluated hair tenofovir (TFV) concentrations as an adherence metric for HIV preexposure prophylaxis during pregnancy and postpartum and compared hair levels with TFV-diphosphate levels in dried blood spots (DBSs)....
15.
Riddler S, Kelly C, Hoesley C, Ho K, Piper J, Edick S, et al.
J Infect Dis
. 2024 Apr;
230(3):696-705.
PMID: 38655842
Background: On-demand topical products could be an important tool for human immunodeficiency virus (HIV) prevention. We evaluated the safety, pharmacokinetics, and ex vivo pharmacodynamics of a tenofovir alafenamide/elvitegravir (TAF/EVG, 20 ...
16.
Coyle R, Morrow M, Mann S, Mainella V, Ellis S, Schwab S, et al.
Clin Infect Dis
. 2024 Apr;
79(5):1233-1241.
PMID: 38636950
Background: QUANTI-TAF aimed to establish tenofovir-diphosphate (TFV-DP)/emtricitabine-triphosphate (FTC-TP) adherence benchmarks in dried blood spots (DBS) for persons with human immunodeficiency virus (PWH) receiving tenofovir alafenamide/emtricitabine (TAF/FTC)-based antiretroviral therapy (ART). Methods:...
17.
Wijstma E, Jongen V, Boyd A, van den Elshout M, de Vries H, Davidovich U, et al.
AIDS
. 2024 Mar;
38(8):1248-1256.
PMID: 38518076
Objective: We assessed the association and concordance between self-reported oral pre-exposure prophylaxis (PrEP) intake in a diary app and intraerythrocytic drug metabolite concentrations. Design: AMPrEP was a prospective demonstration study...
18.
Pons-Faudoa F, Di Trani N, Capuani S, Facchi I, Wood A, Nehete B, et al.
J Control Release
. 2023 Dec;
366:18-27.
PMID: 38142963
Treatment nonadherence is a pressing issue in people living with HIV (PLWH), as they require lifelong therapy to maintain viral suppression. Poor adherence leads to antiretroviral (ARV) resistance, transmission to...
19.
Huang Y, Zhang L, Karuna S, Andrew P, Juraska M, Weiner J, et al.
Nat Commun
. 2023 Nov;
14(1):7813.
PMID: 38016958
Broadly neutralizing monoclonal antibodies (mAbs) are being developed for HIV-1 prevention. Hence, these mAbs and licensed oral pre-exposure prophylaxis (PrEP) (tenofovir-emtricitabine) can be concomitantly administered in clinical trials. In 48...
20.
Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell G, Sharaf R, et al.
Nat Med
. 2023 Nov;
29(12):3212-3223.
PMID: 37957382
Non-suppressible HIV-1 viremia (NSV) is defined as persistent low-level viremia on antiretroviral therapy (ART) without evidence of ART non-adherence or significant drug resistance. Unraveling the mechanisms behind NSV would broaden...